Australian RNA Therapy Targets Lung Disease at Its Source

Millions of Australians with lung disease may soon have access to a treatment that actually stops their condition from getting worse, not just masks the symptoms.

Researchers at Monash University and Atisama Therapeutics have developed the world's first inhaled RNA therapy designed to target the underlying causes of lung disease. The experimental treatment works by suppressing inflammation and scarring in the lungs before permanent damage occurs.

Around nine million Australians currently live with some form of lung disease. Current treatments mainly focus on managing symptoms like shortness of breath and coughing, but they don't prevent the gradual loss of lung function that many patients experience over time.

The new therapy takes a completely different approach. Delivered through a simple nebulizer, it works at a genetic level to target the disease process itself, aiming to reduce flare-ups, slow lung decline, and improve long-term health outcomes.

The treatment could eventually help patients with chronic obstructive pulmonary disease, which affects one in 20 Australians. Indigenous Australians are hit particularly hard, with around 10 percent living with the condition.

Professor Merlin Thomas, founder of Atisama Therapeutics and leader of the research team, said the current approach isn't good enough. "One in three Australians have a chronic lung disease and face lasting problems with their health," he explained.

Federal Health Minister Mark Butler announced a $15 million grant to support the first human trial, which will assess the safety and effectiveness of the treatment. He said the therapy has the potential to transform lung disease treatment globally.

The Ripple Effect

The breakthrough represents more than just hope for Australian patients. RNA therapies are a new class of medicines that could revolutionize how we treat many chronic diseases worldwide.

The $15 million grant is part of almost $300 million recently awarded through the Medical Research Future Fund to support innovative health research. This investment signals Australia's growing role as a global leader in medical innovation, creating jobs and expertise that will benefit future generations.

If successful, the therapy could change the trajectory of lung disease for millions of people worldwide who currently face declining health with limited options.

For the first time, patients may be able to look forward to not just living with lung disease, but actively fighting back against it.